WallStreetZenWallStreetZen

NASDAQ: FWBI
First Wave Biopharma Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for FWBI

Based on 1 analyst offering 12 month price targets for First Wave Biopharma Inc.
Min Forecast
$9.00+389.13%
Avg Forecast
$9.00+389.13%
Max Forecast
$9.00+389.13%

Should I buy or sell FWBI stock?

Based on 2 analysts offering ratings for First Wave Biopharma Inc.
Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their FWBI stock forecasts and price targets.

FWBI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Roth Capital
Bottom 18%
18
Strong BuyMaintains$9.00+389.13%2022-05-26
Maxim Group
Bottom 4%
4
HoldDowngradesN/AN/A2021-12-07

1 of 1

Forecast return on equity

Is FWBI forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is FWBI forecast to generate an efficient return on assets?
Company
-1,664.4%
Industry
13.57%
FWBI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FWBI earnings per share forecast

What is FWBI's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$62.61
Avg 2 year Forecast
-$53.45
Avg 3 year Forecast
-$57.66

FWBI revenue forecast

What is FWBI's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$7.2M
Avg 2 year Forecast
$6.4M
Avg 3 year Forecast
$11.1M

FWBI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FWBI$1.84$9.00+389.13%Buy
PALI$0.11$5.00+4,445.45%Buy
SPRC$0.90$20.00+2,122.22%Strong Buy
BNTC$0.35$4.00+1,042.86%Buy
BXRX$0.27$3.25+1,117.23%Strong Buy

First Wave Biopharma Stock Forecast FAQ

Is First Wave Biopharma Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: FWBI) stock is to Buy FWBI stock.

Out of 2 analysts, 1 (50%) are recommending FWBI as a Strong Buy, 0 (0%) are recommending FWBI as a Buy, 1 (50%) are recommending FWBI as a Hold, 0 (0%) are recommending FWBI as a Sell, and 0 (0%) are recommending FWBI as a Strong Sell.

If you're new to stock investing, here's how to buy First Wave Biopharma stock.

What is FWBI's earnings growth forecast for 2022-2024?

(NASDAQ: FWBI) First Wave Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

First Wave Biopharma's earnings in 2022 is -$57,672,769.On average, 2 Wall Street analysts forecast FWBI's earnings for 2022 to be -$86,798,121, with the lowest FWBI earnings forecast at -$104,501,555, and the highest FWBI earnings forecast at -$69,108,551. On average, 2 Wall Street analysts forecast FWBI's earnings for 2023 to be -$74,099,339, with the lowest FWBI earnings forecast at -$94,090,217, and the highest FWBI earnings forecast at -$54,122,323.

In 2024, FWBI is forecast to generate -$79,935,788 in earnings, with the lowest earnings forecast at -$79,935,788 and the highest earnings forecast at -$79,935,788.

What is FWBI's revenue growth forecast for 2022-2024?

(NASDAQ: FWBI) First Wave Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

First Wave Biopharma's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast FWBI's revenue for 2022 to be $9,939,986, with the lowest FWBI revenue forecast at $9,939,986, and the highest FWBI revenue forecast at $9,939,986. On average, 1 Wall Street analysts forecast FWBI's revenue for 2023 to be $8,927,965, with the lowest FWBI revenue forecast at $8,927,965, and the highest FWBI revenue forecast at $8,927,965.

In 2024, FWBI is forecast to generate $15,429,853 in revenue, with the lowest revenue forecast at $15,429,853 and the highest revenue forecast at $15,429,853.

What is FWBI's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: FWBI) forecast ROA is -1,664.4%, which is lower than the forecast US Biotechnology industry average of 13.57%.

What is FWBI's Price Target?

According to 1 Wall Street analyst that have issued a 1 year FWBI price target, the average FWBI price target is $9.00, with the highest FWBI stock price forecast at $9.00 and the lowest FWBI stock price forecast at $9.00.

The Wall Street analyst predicted that First Wave Biopharma's share price could reach $9.00 by May 26, 2023. The average First Wave Biopharma stock price prediction forecasts a potential upside of 389.13% from the current FWBI share price of $1.84.

What is FWBI's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: FWBI) First Wave Biopharma's current Earnings Per Share (EPS) is -$120.30. On average, analysts forecast that FWBI's EPS will be -$62.61 for 2022, with the lowest EPS forecast at -$75.38, and the highest EPS forecast at -$49.85. On average, analysts forecast that FWBI's EPS will be -$53.45 for 2023, with the lowest EPS forecast at -$67.87, and the highest EPS forecast at -$39.04. In 2024, FWBI's EPS is forecast to hit -$57.66 (min: -$57.66, max: -$57.66).

What is FWBI's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: FWBI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.